Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Effects of Tirzepatide on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Obese Patients: Insights from a Multicenter Real-World Study

  • By

  • Martina Galasso

  • Ludovica Verde

  • Renato Patrone

  • Giovanni Ragozzino

  • Giuseppe Annunziata

  • Annamaria Colao

  • Luigi Barrea

  • Giovanna Muscogiuri

  • July 6, 2026

Share

  • 1

    Tirzepatide is a dual GIP and GLP-1 receptor agonist that shows promise in treating metabolic dysfunction-associated steatotic liver disease (MASLD).

  • 2

    In a study of 23 obese patients with MASLD, tirzepatide treatment for 3 months resulted in significant reductions in body weight and waist circumference.

  • 3

    Significant improvements were observed in metabolic parameters, including fasting glucose, HbA1c, insulin, and inflammatory markers after tirzepatide treatment.

  • 4

    Liver enzymes and the Fatty Liver Index (FLI) significantly decreased, indicating improvements in hepatic steatosis after tirzepatide therapy.

  • 5

    Δhs-CRP was identified as the only independent predictor of ΔFLI, explaining 29.8% of the variance in liver fat improvement.

Original Source(s)

Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study

  • by Martina Galasso, Ludovica Verde, Renato Patrone, Giovanni Ragozzino, Giuseppe Annunziata, Annamaria Colao, Luigi Barrea, Giovanna Muscogiuri

  • July 6, 2026

Related Content

Targeting macrophage metabolism: mechanisms, cellular crosstalk and implications in obesity-associated metabolic diseases

Smoking and Risk of Hepatic Steatosis Within the MASLD Spectrum in Korean Young Adults

Insulin-like growth factor binding proteins in metabolic dysfunction-associated steatotic liver disease